Quick Answer
Tanke Biosciences Corp reported Cash and Equivalents of $6.17 million for fiscal year 2012.
Tanke Biosciences Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2012 | $6.17M | -19.9% |
| 2011 | $7.70M | +246.5% |
| 2010 | $2.22M | +22.2% |
| 2009 | $1.82M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2013 | $5.05M | -54.2% | +7.0% |
| June 30, 2013 | $4.72M | -52.9% | -15.4% |
| March 31, 2013 | $5.59M | -26.9% | -9.4% |
| December 31, 2012 | $6.17M | -19.9% | -44.1% |
| September 30, 2012 | $11.04M | +8.1% | +10.1% |
| June 30, 2012 | $10.03M | — | +31.4% |
| March 31, 2012 | $7.64M | +28.3% | -0.8% |
| December 31, 2011 | $7.70M | +246.5% | -24.6% |
- Tanke Biosciences Corp showed a decrease of -19.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2012 period, Tanke Biosciences Corp’s cash and equivalents has grown by 239.3% (from $1.82 million to $6.17 million).
- The most recent figure is from Tanke Biosciences Corp’s fiscal year 2012 report (Form 10-K), filed with the SEC on April 15, 2013.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: